


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:50:20Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406899" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406899</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>bmjo</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMJ Open</journal-id><journal-id journal-id-type="iso-abbrev">BMJ Open</journal-id><journal-id journal-id-type="pmc-domain-id">1609</journal-id><journal-id journal-id-type="pmc-domain">bmjo</journal-id><journal-id journal-id-type="publisher-id">bmjopen</journal-id><journal-title-group><journal-title>BMJ Open</journal-title></journal-title-group><issn pub-type="epub">2044-6055</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406899</article-id><article-id pub-id-type="pmcid-ver">PMC12406899.1</article-id><article-id pub-id-type="pmcaid">12406899</article-id><article-id pub-id-type="pmcaiid">12406899</article-id><article-id pub-id-type="pmid">40887115</article-id><article-id pub-id-type="doi">10.1136/bmjopen-2024-090422</article-id><article-id pub-id-type="publisher-id">bmjopen-2024-090422</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Protocol</subject></subj-group><subj-group subj-group-type="heading"><subject>Urology</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>1738</subject><subject>1506</subject></subj-group></article-categories><title-group><article-title>Utilisation of artificial intelligence to enhance the detection rates of renal cancer on cross-sectional imaging: protocol for a systematic review and meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0004-5033-9050</contrib-id><name name-style="western"><surname>Ofagbor</surname><given-names initials="O">Ojone</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp"/><xref rid="first-authorship1" ref-type="author-notes">0</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bhardwaj</surname><given-names initials="G">Gaurika</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="first-authorship1" ref-type="author-notes">0</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4563-4344</contrib-id><name name-style="western"><surname>Zhao</surname><given-names initials="Y">Yi</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0006-0384-9423</contrib-id><name name-style="western"><surname>Baana</surname><given-names initials="M">Mohamed</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Arkwazi</surname><given-names initials="M">Murtada</given-names></name><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lami</surname><given-names initials="M">Mariam</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bolton</surname><given-names initials="E">Eva</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="senior-authorship1" ref-type="author-notes">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Heer</surname><given-names initials="R">Rakesh</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="senior-authorship1" ref-type="author-notes">1</xref></contrib><aff id="aff1"><label>1</label><institution content-type="department">Department of Urology</institution>, <institution>Norfolk and Norwich University Hospital</institution>, <addr-line content-type="city">Norwich</addr-line>, <country>UK</country></aff><aff id="aff2"><label>2</label><institution content-type="department">Department of Urology</institution>, <institution>Imperial College Healthcare NHS Trust</institution>, <addr-line content-type="city">London</addr-line>, <country>UK</country></aff><aff id="aff3"><label>3</label><institution>Imperial College London Faculty of Medicine</institution>, <addr-line content-type="city">London</addr-line>, <country>UK</country></aff><aff id="aff4"><label>4</label><institution content-type="department">Department of Urology</institution>, <institution>London North West University Healthcare NHS Trust</institution>, <addr-line content-type="city">Harrow</addr-line>, <country>UK</country></aff><aff id="aff5"><label>5</label><institution>London North West University Healthcare NHS Trust</institution>, <addr-line content-type="city">Harrow</addr-line>, <country>UK</country></aff></contrib-group><author-notes><fn><p>Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p></fn><fn fn-type="COI-statement" id="fn5"><p>None declared.</p></fn><corresp id="cor1">Dr Ojone Ofagbor; <email xlink:href="OJ_OFAGBOR@doctors.org.uk">OJ_OFAGBOR@doctors.org.uk</email></corresp><fn fn-type="other" id="first-authorship1"><p>OO and GB are joint first authors.</p></fn><fn fn-type="other" id="senior-authorship1"><p>EB and RH are joint senior authors.</p></fn></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>31</day><month>8</month><year>2025</year></pub-date><volume>15</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">494363</issue-id><elocation-id>e090422</elocation-id><history><date date-type="received"><day>25</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>24</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>31</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:&#160;<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="bmjopen-15-8.pdf"/><self-uri xlink:title="pdf" xlink:href="bmjopen-15-8.pdf"/><abstract><sec><title> Abstract</title></sec><sec><title>Introduction</title><p>The incidence of renal cell carcinoma has steadily been on the increase due to the increased use of imaging to identify incidental masses. Although survival has also improved because of early detection, overdiagnosis and overtreatment of benign renal masses are associated with significant morbidity, as patients with a suspected renal malignancy on imaging undergo invasive and risky procedures for a definitive diagnosis. Therefore, accurately characterising a renal mass as benign or malignant on imaging is paramount to improving patient outcomes. Artificial intelligence (AI) poses an exciting solution to the problem, augmenting traditional radiological diagnosis to increase detection accuracy. This report aims to investigate and summarise the current evidence about the diagnostic accuracy of AI in characterising renal masses on imaging.</p></sec><sec><title>Methods and analysis</title><p>This will involve systematically searching PubMed, MEDLINE, Embase, Web of Science, Scopus and Cochrane databases. Publications of research that have evaluated the use of automated AI, fully or to some extent, in cross-sectional imaging for diagnosing or characterising malignant renal tumours will be included if published between July 2016 and June 2025 and in English. The protocol adheres to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols 2015 checklist. The Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) score will be used to evaluate the quality and risk of bias across included studies. Furthermore, in line with Checklist for Artificial Intelligence in Medical Imaging recommendations, studies will be evaluated for including the minimum necessary information on AI research reporting.</p></sec><sec><title>Ethics and dissemination</title><p>Ethical clearance will not be necessary for conducting this systematic review, and results will be disseminated through peer-reviewed publications and presentations at both national and international conferences.</p></sec><sec><title>PROSPERO registration number</title><p>CRD42024529929.</p></sec></abstract><kwd-group><kwd>Artificial Intelligence</kwd><kwd>Kidney tumours</kwd><kwd>Urological tumours</kwd><kwd>Meta-Analysis</kwd><kwd>GENITOURINARY MEDICINE</kwd><kwd>RADIOLOGY &amp; IMAGING</kwd></kwd-group><funding-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>CTRQQR-2021\100009</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>STRENGTHS AND LIMITATIONS OF THIS STUDY</title></caption><list list-type="bullet" list-content="ul"><list-item><p>This protocol leans on the strength of Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) and Checklist for Artificial Intelligence in Medical Imaging to reduce bias and improve quality. It will also incorporate subgroup and sensitivity analyses to explore the variability among the studies included.</p></list-item><list-item><p>Artificial intelligence (AI)-specific metrics like the F1 score and precision-recall area under the curve will be used to address limitations inherent in traditional pooled analysis, such as the imbalance of class size favouring large classes and minimising the impact of smaller classes.</p></list-item><list-item><p>The scarcity of long-term data on AI technology in Nephro-urology due to the novelty of this field may hinder the impact of the output of this study and limit its correlation to clinical outcomes.</p></list-item><list-item><p>Limiting this to the English language may reduce the number of eligible studies for inclusion.</p></list-item></list></boxed-text><sec sec-type="background" id="s1"><title>Background</title><p> Cancer of the kidney accounts for 3% of all cancers worldwide and has a rising incidence and mortality rate, accounting for 400&#8201;000 new cases and 175&#8201;000 deaths annually.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref> Solid renal neoplasms encompass a large family of malignant and benign entities of different histological patterns, warranting different management options. The most common and aggressive renal malignancy in the world is renal cell carcinoma (RCC), and its most common subtype is the clear cell type (ccRCC).<xref rid="R2" ref-type="bibr"><sup>2 3</sup></xref> These classifications impact the clinical course of the disease and prognosis. The incidence of RCC has been rising, likely due to increased abdominal imaging for other reasons, which then identify incidental renal masses.<xref rid="R4" ref-type="bibr"><sup>4 5</sup></xref></p><p>The acceptable standard of care according to the European Association of Urology for renal masses is multiphasic cross-sectional imaging for initial diagnosis and biopsy and histology for definitive diagnosis.<xref rid="R6" ref-type="bibr"><sup>6</sup></xref> Patients with radiologically indeterminate renal masses may undergo percutaneous renal biopsies, which have a high risk of misdiagnosis and a theoretical risk of tumour seeding, or partial and total nephrectomies, which are both associated with morbidity.<xref rid="R7" ref-type="bibr"><sup>7</sup></xref> These &#8216;radiological indeterminate renal masses&#8217; are those difficult to characterise adequately by radiologists and constitute as many as 5%&#8211;8% of CT examinations.<xref rid="R8" ref-type="bibr"><sup>8</sup></xref> Accurate identification of benign renal masses on imaging is the cornerstone of improving patient outcomes by avoiding overinvestigation and treatment.<xref rid="R7" ref-type="bibr"><sup>7</sup></xref></p><p>The challenge, therefore, is to enhance the radiologist&#8217;s ability to unequivocally differentiate benign masses from cancer on cross-sectional imaging such as CT scan, MRI or contrast-enhanced ultrasound scan (USS) to reduce surgical intervention for these masses.<xref rid="R2" ref-type="bibr"><sup>2 9</sup></xref> As many as 16%&#8211;19% of surgically removed renal masses end up being benign.<xref rid="R10" ref-type="bibr"><sup>10</sup></xref> Crucially, interobserver variability between radiologists in the assessment of renal masses suggests variability in the management offered to patients.<xref rid="R11" ref-type="bibr"><sup>11</sup></xref> Due to the increase in the incidence of renal tumours, the diagnostic accuracy of cross-sectional imaging requires development for higher precision.<xref rid="R12" ref-type="bibr"><sup>12</sup></xref> The role of improved image processing and interpretation with the assistance of artificial intelligence (AI) is therefore cut out.</p><p>AI offers an opportunity to augment traditional radiological diagnosis to increase detection accuracy.<xref rid="R13" ref-type="bibr"><sup>13</sup></xref> AI is the ability of machines to perform tasks that typically require human intelligence.<xref rid="R14" ref-type="bibr"><sup>14</sup></xref> Deep learning is a facet of AI which allows machines to learn from data and improve their performance over time, autonomously and without human programming.<xref rid="R14" ref-type="bibr"><sup>14</sup></xref> Radiomics places deep learning in the context of medical imaging by analysing vast amounts of quantitative data to uncover hidden patterns or relationships which are not visible in conventional imaging.<xref rid="R15" ref-type="bibr"><sup>15</sup></xref></p><p>Radiomics can aid in decision-making for indeterminate renal masses on CT and MRI, using tools such as texture analysis in a region of interest.<xref rid="R16" ref-type="bibr"><sup>16</sup></xref> Heterogeneity is an important feature distinguishing between benign and malignant pathology; however, malignant renal masses are often low in attenuation, making this difficult to analyse.<xref rid="R17" ref-type="bibr"><sup>17</sup></xref> Furthermore, angiomyolipomas with low-fat content can appear similar to RCC.<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> Similarly, oncocytomas can resemble chromophobe RCCs due to their cell composition and morphology on imaging.<xref rid="R19" ref-type="bibr"><sup>19</sup></xref> Studies have shown that in each of these cases, texture analysis can provide an objective assessment to increase the accuracy of detection.<xref rid="R16" ref-type="bibr"><sup>16</sup></xref></p><p>Deep learning and radiomics are powerful solutions to existing problems such as interobserver variability and missed or incorrectly characterised renal masses. Ultimately, this can streamline workflow processes in radiology departments by expediting image interpretation and flagging suspicious lesions for further scrutiny.<xref rid="R20" ref-type="bibr"><sup>20</sup></xref></p><p>Although deep learning shows promise in differentiating renal masses, the feasibility of routine clinical application remains to be determined.<xref rid="R21" ref-type="bibr"><sup>21</sup></xref> Importantly, most studies evaluating its use are retrospective and therefore prone to selection bias.<xref rid="R22" ref-type="bibr"><sup>22</sup></xref> Furthermore, the variety of radiomic models and texture analysis methods has resulted in heterogeneous evidence and a lack of external validation.<xref rid="R23" ref-type="bibr"><sup>23</sup></xref> There are unlimited radiomic features that can be extracted from data sets, which can result in the algorithm making accurate predictions on training data, with the inability to apply these features to new data sets.<xref rid="R24" ref-type="bibr"><sup>24</sup></xref> This inability to generalise is referred to as an overfitting algorithm.<xref rid="R24" ref-type="bibr"><sup>24</sup></xref></p><p>This review aims to summarise and investigate the current evidence of AI&#8217;s diagnostic accuracy in characterising renal masses on imaging. The expected outcome will be a summary of measured improvements in imaging interpretation accuracy in diagnosing renal cancer due to AI.</p></sec><sec id="s2"><title>Methods and analysis</title><p>This systematic review, in keeping with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols 2015 checklist, has been prospectively registered with PROSPERO with a database number (CRD42024529929) and prospective methodology defined prior to the commencement of the study.<xref rid="R25" ref-type="bibr"><sup>25</sup></xref> Studies meeting the criteria will be systematically reviewed to identify key results, including sensitivity, specificity, area under the curve (AUC), positive predictive value (PPV), negative predictive value (NPV), training and validation losses. Through statistical analysis of commonly themed studies, pooled sensitivities, specificities, PPVs and NPVs will then be derived.</p><sec id="s2-1"><title>Search methodology</title><p>The review will include a systematic search through PubMed, MEDLINE, Embase, Web of Science, Scopus and Cochrane databases. Using key search terms with appropriate Boolean operators, articles published from July 2016 to June 2025 will be explored for fit. Medical subject heading terms to be used will include &#8220;kidney&#8221;, &#8220;renal&#8221;, &#8220;cancer&#8221;, &#8220;malignancy&#8221;, &#8220;neoplasm&#8221;, &#8220;Carcinoma&#8221;, &#8220;diagnosis&#8221;, &#8220;characterisation&#8221;, &#8220;differentiation&#8221;, synonyms of cross-sectional imaging, &#8220;CT&#8221;, &#8220;MRI&#8221; and &#8220;CEUS&#8221; as well as synonyms of &#8220;artificial intelligence (AI)&#8220;, &#8220;machine learning (ML)&#8221; and &#8220;deep learning (DL)". This search strategy is available in <xref rid="SP1" ref-type="supplementary-material">online supplemental file 1</xref>. The objective is to improve the accuracy and speed of the initial screening process through Rayyan, a semiautomated application designed to facilitate systematic searching. Following this automated process, further search through relevant sources in the references of included papers will be carried out. Finally, where clarifications are required or data sets need to be completed, we would reach out to the corresponding authors for these.</p></sec><sec id="s2-2"><title>Study selection and data extraction</title><p>To conclude the selection process, two researchers (OO and GB) will meticulously review each included abstract at the first stage independently. Relevant papers selected will then be read in full for further review. A third reviewer, YG, will be called on to help resolve any disagreements through discussion and consensus. All this will be documented and presented in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram as per the protocol. Harmonising review criteria will minimise the potential risk of inter-reviewer bias among all reviewers before the exercise.</p></sec><sec id="s2-3"><title>Inclusion and exclusion</title><p>We aim to include all studies that have evaluated the use of automated AI, fully or to some extent, in cross-sectional imaging for the diagnosis or characterisation of malignant renal tumours. These may be prospective or retrospective studies and would include patients who have renal cancer confirmed on histology. The desirable outcome measures will include sensitivities, specificities, PPVs and NPVs as well as AI-specific measures.</p><p>There will be the exclusion of correspondence papers, ongoing studies, case reports and conference abstracts. Other exclusion criteria will be non-English language articles, studies that have not evaluated the use of cross-sectional imaging as the primary diagnostic modality and studies that have included patients with previous histological examinations of the same kidney.</p></sec><sec id="s2-4"><title>Data extraction (table of collection)</title><p><xref rid="T1" ref-type="table">Table 1</xref> details the required data to be gathered from all included studies. The researchers will independently collect these and collate them in a combined data spreadsheet. This will be evaluated for discrepancies and reviewed by a third researcher to achieve consensus. For analysis, key outcome measures will be collected and tabulated, such as true positives and negatives, false positives and negatives. These will be used to further derive the required outcome measures if they are not already given.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><title>Data collection items</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" rowspan="1" colspan="1">Item no.</th><th valign="bottom" rowspan="1" colspan="1">Data title</th><th valign="bottom" rowspan="1" colspan="1">Data type</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">Year of publication</td><td align="left" valign="top" rowspan="1" colspan="1">Study characteristic</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">Study authors</td><td align="left" valign="top" rowspan="1" colspan="1">Study characteristic</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">Experimental design</td><td align="left" valign="top" rowspan="1" colspan="1">Study characteristic</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1">Patient population</td><td align="left" valign="top" rowspan="1" colspan="1">Demographics</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="left" valign="top" rowspan="1" colspan="1">Study size</td><td align="left" valign="top" rowspan="1" colspan="1">Demographics</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">Type of MRI/CT imaging used</td><td align="left" valign="top" rowspan="1" colspan="1">Methodology</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="left" valign="top" rowspan="1" colspan="1">Type of MRI/CT scoring system used</td><td align="left" valign="top" rowspan="1" colspan="1">Methodology</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="left" valign="top" rowspan="1" colspan="1">Type of AI models used</td><td align="left" valign="top" rowspan="1" colspan="1">Methodology</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">9</td><td align="left" valign="top" rowspan="1" colspan="1">Predictive performances</td><td align="left" valign="top" rowspan="1" colspan="1">Outcome</td></tr></tbody></table><table-wrap-foot><fn id="T1_FN1" fn-type="abbr"><p>AI, artificial intelligence.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-5"><title>Endpoints</title><p>The primary outcome to be determined is a statistically significant quantified measure of advancement in the accuracy of imaging techniques aided by AI in the detection rates of renal cancer.</p></sec><sec id="s2-6"><title>Meta-analysis</title><p>This meta-analysis will involve the amalgamation of quantitative outcomes from appropriately matched studies to derive pooled estimates of diagnostic accuracy for AI-assisted detection of renal cancer on cross-sectional imaging. Once sufficient studies are identified, sensitivity and specificity values will be extracted or derived from reported data. In addition to these traditional diagnostic metrics, we will include AI-specific performance measures, such as F1 score, precision, recall, overall accuracy, precision-recall AUC, training and validation losses, where consistently reported. These metrics will be incorporated into the primary analysis or analysed descriptively if heterogeneity in reporting precludes pooling. Where available, training and validation loss curves will also be reviewed to assess model overfitting and generalisability.</p><p>To account for variability in reported metrics and ensure statistical validity, we will examine the distribution of untransformed, logit-transformed and double-arcsine-transformed proportions using density plots and Shapiro-Wilk tests. The transformation that best approximates a normal distribution will be selected for meta-analysis. Where appropriate, standardised formulas (eg, Zhang and Yu&#8217;s method for converting ORs to risk ratios) will be applied to harmonise effect measures across studies.</p><p>To investigate potential sources of heterogeneity, we will conduct prespecified subgroup analyses based on imaging modality (CT, MRI, Contrast Enhanced Ultrasound), AI model type (machine learning, deep learning, hybrid), study design (prospective vs retrospective), validation approach (internal vs external) and tumour subtype, where available. Subgroup effects will be assessed using stratified meta-analyses and meta-regression, with interaction testing used to evaluate statistical significance.</p><p>Interstudy variability will be quantified using the I&#178; statistic. If heterogeneity is substantial, a random-effects model will be fitted to estimate the summary effect. Influential studies will be identified through leave-one-out analysis and diagnostic plots, including externally studentised residuals, difference in fits (DFFITS), Cook&#8217;s distances, covariance ratios and hat values. Studies with disproportionate influence will be considered outliers and excluded in sensitivity analyses, after which the model will be refitted to derive a final summary estimate.</p><p>All statistical analyses and visualisations will be conducted using the R statistical environment, employing the &#8216;meta&#8217;, &#8216;metafor&#8217; and &#8216;mvmeta&#8217; packages. Custom scripts and transformation procedures will be documented and made available in supplementary materials to support transparency and reproducibility.</p></sec><sec id="s2-7"><title>Risk of bias in individual studies</title><p>The quality of the methodology of each study will be assessed within four domains, namely, the patient selection, index test, reference standard and flow and timing. These domains will be evaluated to ascertain the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) score, which will be used to determine the quality and risk of bias across studies. Signalling questions within each domain will be used to assess the quality of each study. Furthermore, as studies to be included will involve work on radiological images, the Checklist for Artificial Intelligence in Medical Imaging checklist will be used to determine appropriateness. Image reconstruction data, text analysis and workflow optimisation are some of the minimum characteristics that must be included.<xref rid="R26" ref-type="bibr"><sup>26</sup></xref> Two reviewers (OO and GB) will independently carry out this process and derive consensus if any disparities arise through dialogue. This process would determine how reliable and applicable the data is. The bias assessment will inform evidence synthesis. Any studies deemed of inadequate quality or of substantial bias will be separated or, if included, will be appropriately discussed.</p></sec></sec><sec sec-type="discussion" id="s3"><title>Discussion</title><p>Improving the ability of cross-sectional imaging to detect renal cancers accurately provides a potential role for AI. The magnitude and nature of this role remain to be defined. Through this meta-analysis, we hope to provide evidence that defines the role of AI in the detection of renal cancers and outlines its clinical significance.</p><sec id="s3-1"><title>Limitations</title><p>This project may face a few limitations. First, as neural networks employed in machine learning vary, the data collected may be reported differently, potentially confounding our findings. Second, issues of heterogeneity of reporting protocols may arise. Lastly, as AI-assisted imaging in renal masses is relatively novel, there may be an inadequate number of studies to review.</p></sec></sec><sec id="s4"><title>Ethics and dissemination</title><p>Ethical clearance will not be necessary for conducting this systematic review. The intention following the achievement of our objective is to publish findings in a peer-reviewed journal and to present key findings at both national and international conferences. This will hopefully promote an understanding of current AI and deep learning protocols, thereby advancing current practice. Existing systems may benefit from this through evidence that supports supervised and unsupervised usage of AI to refine image processing and reporting protocols in the detection of renal cancers.</p><sec id="s4-1"><title>Patient and public involvement</title><p>There will be no patient or public involvement in this study.</p></sec><sec id="s4-2"><title>Trial status</title><list list-type="bullet" list-content="ul"><list-item><p>Preliminary searches: started.</p></list-item><list-item><p>Piloting of the study selection process: started.</p></list-item><list-item><p>Formal screening: not started.</p></list-item><list-item><p>Data extraction: not started.</p></list-item><list-item><p>Risk of bias assessment: not started.</p></list-item><list-item><p>Data analysis: not started.</p></list-item></list></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supplementary material</title><supplementary-material id="SP1" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.1136/bmjopen-2024-090422</object-id><label>online supplemental file 1</label><media xlink:href="bmjopen-15-8-s001.docx" id="d67e479" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> Funding provided by Cancer Research UK CTRQQR-2021\100009.</p></fn><fn fn-type="other"><p><bold>Prepub:</bold> Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<ext-link xlink:href="https://doi.org/10.1136/bmjopen-2024-090422" ext-link-type="uri">https://doi.org/10.1136/bmjopen-2024-090422</ext-link>).</p></fn><fn fn-type="other"><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn><fn fn-type="other"><p><bold>Patient consent for publication:</bold> Not applicable.</p></fn><fn fn-type="other"><p><bold>Patient and public involvement:</bold> Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cirillo</surname><given-names>L</given-names></name><name name-style="western"><surname>Innocenti</surname><given-names>S</given-names></name><name name-style="western"><surname>Becherucci</surname><given-names>F</given-names></name></person-group><article-title>Global epidemiology of kidney cancer</article-title><source>Nephrol Dial Transplant</source><year>2024</year><volume>39</volume><fpage>920</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfae036</pub-id><pub-id pub-id-type="pmid">38341277</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>X-Y</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Q-X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><etal>et al</etal></person-group><article-title>Radiologic-Radiomic Machine Learning Models for Differentiation of Benign and Malignant Solid Renal Masses: Comparison With Expert-Level Radiologists</article-title><source><italic toggle="yes">AJR Am J Roentgenol</italic></source><year>2020</year><volume>214</volume><fpage>W44</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.2214/AJR.19.21617</pub-id><pub-id pub-id-type="pmid">31553660</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shehata</surname><given-names>M</given-names></name><name name-style="western"><surname>Alksas</surname><given-names>A</given-names></name><name name-style="western"><surname>Abouelkheir</surname><given-names>RT</given-names></name><etal>et al</etal></person-group><article-title>A Comprehensive Computer-Assisted Diagnosis System for Early Assessment of Renal Cancer Tumors</article-title><source><italic toggle="yes">Sensors (Basel</italic>)</source><year>2021</year><volume>21</volume><elocation-id>4928</elocation-id><pub-id pub-id-type="doi">10.3390/s21144928</pub-id><pub-id pub-id-type="pmid">34300667</pub-id><pub-id pub-id-type="pmcid">PMC8309718</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Capitanio</surname><given-names>U</given-names></name><name name-style="western"><surname>Montorsi</surname><given-names>F</given-names></name></person-group><article-title>Renal cancer</article-title><source>Lancet</source><year>2016</year><volume>387</volume><fpage>894</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(15)00046-X</pub-id><pub-id pub-id-type="pmid">26318520</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krishna</surname><given-names>S</given-names></name><name name-style="western"><surname>Leckie</surname><given-names>A</given-names></name><name name-style="western"><surname>Kielar</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Imaging of Renal Cancer</article-title><source>Semin Ultrasound CT MR</source><year>2020</year><volume>41</volume><fpage>152</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1053/j.sult.2019.12.004</pub-id><pub-id pub-id-type="pmid">32446429</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ljungberg</surname><given-names>B</given-names></name><name name-style="western"><surname>Albiges</surname><given-names>L</given-names></name><name name-style="western"><surname>Abu-Ghanem</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update</article-title><source>Eur Urol</source><year>2022</year><volume>82</volume><fpage>399</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2022.03.006</pub-id><pub-id pub-id-type="pmid">35346519</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sohlberg</surname><given-names>EM</given-names></name><name name-style="western"><surname>Metzner</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Leppert</surname><given-names>JT</given-names></name></person-group><article-title>The Harms of Overdiagnosis and Overtreatment in Patients with Small Renal Masses: A Mini-review</article-title><source>Eur Urol Focus</source><year>2019</year><volume>5</volume><fpage>943</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.euf.2019.03.006</pub-id><pub-id pub-id-type="pmid">30905599</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fowler</surname><given-names>C</given-names></name><name name-style="western"><surname>Reznek</surname><given-names>RH</given-names></name></person-group><article-title>The indeterminate renal mass</article-title><source><italic toggle="yes">Imaging</italic></source><year>2001</year><volume>13</volume><fpage>27</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1259/img.13.1.130027</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>Differentiating Benign from Malignant Renal Tumors Using <sc>t2</sc> &#8208; and Diffusion&#8208;Weighted Images: A Comparison of Deep Learning and Radiomics Models Versus Assessment from Radiologists</article-title><source>J Magn Reson Imaging</source><year>2022</year><volume>55</volume><fpage>1251</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1002/jmri.27900</pub-id><pub-id pub-id-type="pmid">34462986</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uhlig</surname><given-names>J</given-names></name><name name-style="western"><surname>Biggemann</surname><given-names>L</given-names></name><name name-style="western"><surname>Nietert</surname><given-names>MM</given-names></name><etal>et al</etal></person-group><article-title>Discriminating malignant and benign clinical T1 renal masses on computed tomography: A pragmatic radiomics and machine learning approach</article-title><source>Medicine (Baltimore)</source><year>2020</year><volume>99</volume><elocation-id>e19725</elocation-id><pub-id pub-id-type="doi">10.1097/MD.0000000000019725</pub-id><pub-id pub-id-type="pmid">32311963</pub-id><pub-id pub-id-type="pmcid">PMC7220487</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guti&#233;rrez Hidalgo</surname><given-names>B</given-names></name><name name-style="western"><surname>G&#243;mez Rivas</surname><given-names>J</given-names></name><name name-style="western"><surname>de la Parra</surname><given-names>I</given-names></name><etal>et al</etal></person-group><article-title>The Use of Radiomic Tools in Renal Mass Characterization</article-title><source><italic toggle="yes">Diagnostics (Basel</italic>)</source><year>2023</year><volume>13</volume><elocation-id>2743</elocation-id><pub-id pub-id-type="doi">10.3390/diagnostics13172743</pub-id><pub-id pub-id-type="pmid">37685281</pub-id><pub-id pub-id-type="pmcid">PMC10487148</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Musaddaq</surname><given-names>B</given-names></name><name name-style="western"><surname>Musaddaq</surname><given-names>T</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Renal Cell Carcinoma: The Evolving Role of Imaging in the 21st Century</article-title><source>Semin Ultrasound CT MR</source><year>2020</year><volume>41</volume><fpage>344</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1053/j.sult.2020.05.002</pub-id><pub-id pub-id-type="pmid">32620224</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalifa</surname><given-names>M</given-names></name><name name-style="western"><surname>Albadawy</surname><given-names>M</given-names></name></person-group><article-title>AI in diagnostic imaging: Revolutionising accuracy and efficiency</article-title><source>Comp Method Prog Biomed Upd</source><year>2024</year><volume>5</volume><fpage>100146</fpage><pub-id pub-id-type="doi">10.1016/j.cmpbup.2024.100146</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gore</surname><given-names>JC</given-names></name></person-group><article-title>Artificial intelligence in medical imaging</article-title><source>Magn Reson Imaging</source><year>2020</year><volume>68</volume><fpage>A1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.mri.2019.12.006</pub-id><pub-id pub-id-type="pmid">31857130</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tramanzoli</surname><given-names>P</given-names></name><name name-style="western"><surname>Castellani</surname><given-names>D</given-names></name><name name-style="western"><surname>De Stefano</surname><given-names>V</given-names></name><etal>et al</etal></person-group><article-title>Radiomics vs radiologist in bladder and renal cancer. Results from a systematic review</article-title><source>Cent European J Urol</source><year>2023</year><volume>76</volume><fpage>12</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.5173/ceju.2023.252</pub-id><pub-id pub-id-type="pmcid">PMC10091893</pub-id><pub-id pub-id-type="pmid">37064257</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Soule</surname><given-names>E</given-names></name><name name-style="western"><surname>Cui</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Usefulness of CT texture analysis in differentiating benign and malignant renal tumours</article-title><source>Clin Radiol</source><year>2020</year><volume>75</volume><fpage>108</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.crad.2019.09.131</pub-id><pub-id pub-id-type="pmid">31668402</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>NY</given-names></name><name name-style="western"><surname>Lubner</surname><given-names>MG</given-names></name><name name-style="western"><surname>Nystrom</surname><given-names>JT</given-names></name><etal>et al</etal></person-group><article-title>Utility of CT Texture Analysis in Differentiating Low-Attenuation Renal Cell Carcinoma From Cysts: A Bi-Institutional Retrospective Study</article-title><source><italic toggle="yes">AJR Am J Roentgenol</italic></source><year>2019</year><volume>213</volume><fpage>1259</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.2214/AJR.19.21182</pub-id><pub-id pub-id-type="pmid">31386573</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Milner</surname><given-names>J</given-names></name><name name-style="western"><surname>McNeil</surname><given-names>B</given-names></name><name name-style="western"><surname>Alioto</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Fat poor renal angiomyolipoma: patient, computerized tomography and histological findings</article-title><source>J Urol</source><year>2006</year><volume>176</volume><fpage>905</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2006.04.016</pub-id><pub-id pub-id-type="pmid">16890650</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Leon</surname><given-names>AD</given-names></name><name name-style="western"><surname>Kapur</surname><given-names>P</given-names></name><name name-style="western"><surname>Pedrosa</surname><given-names>I</given-names></name></person-group><article-title>Radiomics in Kidney Cancer: MR Imaging</article-title><source>Magn Reson Imaging Clin N Am</source><year>2019</year><volume>27</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.mric.2018.08.005</pub-id><pub-id pub-id-type="pmid">30466904</pub-id><pub-id pub-id-type="pmcid">PMC6554741</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stanzione</surname><given-names>A</given-names></name><name name-style="western"><surname>Cuocolo</surname><given-names>R</given-names></name><name name-style="western"><surname>Ugga</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>Oncologic Imaging and Radiomics: A Walkthrough Review of Methodological Challenges</article-title><source>Cancers (Basel)</source><year>2022</year><volume>14</volume><elocation-id>4871</elocation-id><pub-id pub-id-type="doi">10.3390/cancers14194871</pub-id><pub-id pub-id-type="pmid">36230793</pub-id><pub-id pub-id-type="pmcid">PMC9562166</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roussel</surname><given-names>E</given-names></name><name name-style="western"><surname>Capitanio</surname><given-names>U</given-names></name><name name-style="western"><surname>Kutikov</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review</article-title><source>Eur Urol</source><year>2022</year><volume>81</volume><fpage>476</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2022.01.040</pub-id><pub-id pub-id-type="pmid">35216855</pub-id><pub-id pub-id-type="pmcid">PMC9844544</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelly</surname><given-names>BS</given-names></name><name name-style="western"><surname>Judge</surname><given-names>C</given-names></name><name name-style="western"><surname>Bollard</surname><given-names>SM</given-names></name><etal>et al</etal></person-group><article-title>Radiology artificial intelligence: a systematic review and evaluation of methods (RAISE)</article-title><source>Eur Radiol</source><year>2022</year><volume>32</volume><fpage>7998</fpage><lpage>8007</lpage><pub-id pub-id-type="doi">10.1007/s00330-022-08784-6</pub-id><pub-id pub-id-type="pmid">35420305</pub-id><pub-id pub-id-type="pmcid">PMC9668941</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Elbanan</surname><given-names>MG</given-names></name><name name-style="western"><surname>Luna</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Radiomics in Abdominopelvic Solid-Organ Oncologic Imaging: Current Status</article-title><source><italic toggle="yes">AJR Am J Roentgenol</italic></source><year>2022</year><volume>219</volume><fpage>985</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.2214/AJR.22.27695</pub-id><pub-id pub-id-type="pmid">35766531</pub-id><pub-id pub-id-type="pmcid">PMC10616929</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#252;hlbauer</surname><given-names>J</given-names></name><name name-style="western"><surname>Egen</surname><given-names>L</given-names></name><name name-style="western"><surname>Kowalewski</surname><given-names>K-F</given-names></name><etal>et al</etal></person-group><article-title>Radiomics in Renal Cell Carcinoma-A Systematic Review and Meta-Analysis</article-title><source>Cancers (Basel)</source><year>2021</year><volume>13</volume><elocation-id>1348</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13061348</pub-id><pub-id pub-id-type="pmid">33802699</pub-id><pub-id pub-id-type="pmcid">PMC8002585</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shamseer</surname><given-names>L</given-names></name><name name-style="western"><surname>Moher</surname><given-names>D</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation</article-title><source>BMJ</source><year>2015</year><volume>350</volume><elocation-id>g7647</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.g7647</pub-id><pub-id pub-id-type="pmid">25555855</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mongan</surname><given-names>J</given-names></name><name name-style="western"><surname>Moy</surname><given-names>L</given-names></name><name name-style="western"><surname>Kahn</surname><given-names>CE</given-names></name></person-group><article-title>Checklist for Artificial Intelligence in Medical Imaging (CLAIM): A Guide for Authors and Reviewers</article-title><source><italic toggle="yes">Radiol Artif Intell</italic></source><year>2020</year><volume>2</volume><elocation-id>e200029</elocation-id><pub-id pub-id-type="doi">10.1148/ryai.2020200029</pub-id><pub-id pub-id-type="pmid">33937821</pub-id><pub-id pub-id-type="pmcid">PMC8017414</pub-id></element-citation></ref></ref-list></back><sub-article id="sub-article1" article-type="aggregated-review-documents"><front-stub><title-group><article-title>Review Process File</article-title></title-group><pub-date pub-type="epub"><day>31</day><month>08</month><year>2025</year></pub-date></front-stub><body><fig id="d67e1201" position="anchor" orientation="portrait"><media xlink:href="bmjopen-2024-090422.reviewer_comments.pdf" position="float" orientation="portrait"/></fig></body></sub-article></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>